Health News Releases

  • Today August 27
March 04, 2022 13:50
Hologic Partners With the WTA Tour in Landmark Title Sponsorship
The WTA and Hologic today jointly announced a landmark partnership introducing Hologic as the global title sponsor of the WTA Tour. The multi-year alliance, the largest global sponsorship in WTA hi
March 04, 2022 11:20
The OPTRACT Method: Efficient Human Donor Cornea Transportation Feat & Futuristic Cell Repository in Zero-gravity for Space-age, Anti-aging Research; Strategy by Japanese Scientists.
A much efficient human cadaver donor-corneal transportation method, developed by Japanese scientists, may increase the availability of donated eyes to millions of patients with corneal blindness, wait
March 03, 2022 17:30
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), to
March 03, 2022 17:15
Allscripts to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software
Allscripts Healthcare Solutions (NASDAQ: MDRX) (“Allscripts”) announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris
March 02, 2022 10:15
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
Takeda (TSE:4502/NYSE:TAK) today presented four abstracts including interim real-world data from the observational Phase 4 EMPOWER study of TAKHZYRO® (lanadelumab) as a treatment for people with Hered
March 02, 2022 10:15
FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®
Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S.
March 02, 2022 10:05
Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy
Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochlo
February 28, 2022 15:40
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
February 28, 2022 09:49
Oncocross Begins Phase I Clinical Trial of AI-Developed Drug for Sarcopenia
Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Austral
February 25, 2022 11:00
GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease
GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and the Wyss Center, a non-profit organization dedicated
GI Innovation signed MoU with CellKey for biomarker joint research to develop next-generation innova
February 25, 2022 10:34
GI Innovation and Cellkey to Develop Next-generation Innovative Immuno-oncology through Biomarker Joint Research
GI Innovation, an innovative new drug development company, announced that it signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generatio
February 25, 2022 09:25
New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression
Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® (cladribine tablets) had more favourable relapse outcomes and lon
February 24, 2022 10:00
Protein Hydrolysate Ingredients Market is expected to reach USD 1.0 Billion by 2031, growing at a CAGR of 7.30% during 2021- 2031: Future Market Insights
The global sales of protein hydrolysate ingredients are expected to grow by 6.80% in 2021, reaching 33,268 MT in terms of volume. Future Market Insights (FMI) forecasts that the protein hydrolysate in
February 23, 2022 16:40
rf IDEAS and Key Partners to Spotlight Healthcare IAM Solutions at HIMSS22
rf IDEAS, a global leader in the design and manufacture of credential readers for authentication and logical access, will be on site at the HIMSS22 Conference in Orlando, Florida (Booth #1313) with ke
February 23, 2022 11:43
Taro to Acquire Alchemee From Galderma
Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from G
February 23, 2022 10:50
Kaneka Eurogentec Announces the Successful Production of 25g of mRNA in One Batch
Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization (CDMO), announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for
February 23, 2022 10:00
Laboratory Information Systems Market is slated to increase at a CAGR of 10.2% to reach a valuation of USD 4.2 Billion by 2030: Future Market Insights
Global laboratory information system (LIS) market revenues are set to grow at 10.2% CAGR through 2030, according to an updated edition by Future Market Insights (FMI). The 2022-2030 version of the rep
February 22, 2022 16:00
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment o
February 22, 2022 15:54
Advanced Wound Management Market is projected to grow at a steady pace, exceeding a market valuation of USD 6.5 Billion between 2021 and 2031: Future Market Insights
Growing investments in the healthcare sector, coupled with innovations in advanced wound management products are anticipated to positively shape demand in the upcoming years. With an increasing inc
February 21, 2022 11:55
European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients
February 21, 2022 11:30
Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from th
February 21, 2022 10:35
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study[1,2]
Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission[*] was observed in 65% of patients in both cohorts who were evaluated
February 18, 2022 16:28
Karen L. Ling joins Galderma’s Advisory Committee
Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022. Karen Ling has a tremendous track record
February 18, 2022 09:10
NEC OncoImmunity Publishes a Unique HLA Typing Technology That Discovers New HLA Alleles, and Tumor Specific HLA Alleles
NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized cancer immunotherapy. The co
February 17, 2022 15:20
Vifor Pharma reports sustained growth in 2021
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject®
25 per page50 per page75 per page100 per page